Genmab A/S (OTCMKTS:GNMSF – Get Free Report)’s share price crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $266.48 and traded as low as $218.93. Genmab A/S shares last traded at $218.93, with a volume of 765 shares trading hands.
Genmab A/S Price Performance
The company has a market cap of $15.02 billion, a PE ratio of 19.02 and a beta of 1.06. The business has a 50 day moving average of $252.34 and a 200 day moving average of $265.95.
Genmab A/S (OTCMKTS:GNMSF – Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported $3.13 earnings per share for the quarter. Genmab A/S had a net margin of 29.06% and a return on equity of 20.60%. The firm had revenue of $779.50 million for the quarter.
Genmab A/S Company Profile
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Featured Articles
- Five stocks we like better than Genmab A/S
- 3 Stocks to Consider Buying in October
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- What is a Low P/E Ratio and What Does it Tell Investors?
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
